Online First »
The FDA added everolimus to its Adverse Event Reporting System due to new safety information the agency has received regarding hypertension. Everolimus is indicated for the treatment of renal cell carcinoma in patients who have failed previous treatments.
The FDA has not released any additional information on this decision and "is continuing to evaluate this issue to determine the need for any regulatory action." The addition to the Adverse Event Reporting System relate to pulmonary hypertension and pulmonary arterial hypertension.
Online Exclusive »
(Reuters) - A Polish man who was paralyzed from the chest down in a knife attack can now walk with the aid of a frame after receiving pioneering transplant treatment using cells from his nose.
The technique, described as a breakthrough by a study in the journal Cell Transplantation, involved transplanting what are known as olfactory ensheathing cells into the patient's spinal cord and constructing a "nerve bridge" between two stumps of the damaged spinal column.
Cover Story; American Academy of Pain Management »
Phoenix—As a clinical pharmacy specialist at the Stratton Veterans Affairs Medical Center in Albany, New York, Jeffrey Fudin, PharmD, is prohibited from prescribing or dispensing marijuana. He is a federal government employee and must abide by US law that makes marijuana illegal.
- Improving Men’s Health, Quality of Life, and Cost Outcomes: Evolving Treatment Strategies for Benign Prostatic Hyperplasia
- Building Better COPD Management Programs: Incorporating HEDIS Measures and Clinical Data
- Assessing the Cost/Benefit of Oral MS Therapies on Patient Health and Resource Utilization
- Incorporating HEDIS Measures and Newer Therapies to Improve COPD Treatment Adherence and Outcomes
- Translating Guidelines and Evidence on Newer Anticoagulants to Improved Clinical and Cost Outcomes in AF-Related Stroke
- Opportunities to Reduce the Clinical and Economic Burden of Hyponatremia: Clinical and Pharmacoeconomic Guidance for Managed Care